Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
Astrazenaca has rejected Pfizer's $106 billion bid for the company. CNBC's Meg Tirrell, and Tim Chiang, CRT Capital senior analyst, discuss Pfizer's "opportunistic" strategy, and m&a in the pharma industry.
AstraZeneca's board rejected a $106.5 billion bid from predator Pfizer just hours after it was received, arguing that it is too low.
AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.
U.S. stock index futures pointed to a slightly higher open on Wall Street, ahead of the government’s all-important non-farm payrolls jobs report.
Some of the names on the move ahead of the open.
Pfizer is set to sweeten its bid for British pharma AstraZeneca. CNBC's Catherine Boyle reports on the developments.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
Some of Thursday's midday movers:
CNBC's David Faber digs into a Bloomberg report saying Pfizer is planning to raise its bid for AstraZenaca to $106 billion.
The WHO’s recent warning about germs resistant to antibiotics has raised questions about what pharma companies are doing to fight this.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
CNBC's Catherine Boyle reports on Pfizer's charm offensive as its CEO Ian Read flew in to London for a round of meetings with politicians and investors.
Don't blame Apple for its debt offering or Pfizer for going overseas—blame those who write the US tax code, says NYU Stern Professor Aswath Damodaran.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Sue Noffke, U.K. equities fund manager at Schroders, says Pfizer wants AstraZeneca's oncology drugs pipeline which looks promising.
Can there be a clearer illustration of the chasm between French and UK attitudes to business than this week's M&A headlines, writes Steve Sedgwick.
The euro traded at multi-week highs against the yen early on Tuesday and held firm against the dollar after a strong performance overnight.
Argus Research's John Eade weighs in on growing M&A in the pharma space.